Pressmeddelande

06 Oct, 2017

Cantargia obtains patent approval in USA for the antibody CAN04 in development for treatment of cancer

Cantargia AB (”Cantargia”) today announces that the United States Patent and Trademark Office (“USPTO”) has granted the company’s patent application directed to the product candidate CAN04. The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that USPTO issued in June 2017.

The granted patent no. US 9,796,783 concerns the composition of the product candidate CAN04. The patent gives protection in USA until 2035. In addition to the patent granted in USA, Cantargia obtained approval in Europe in August 2017. The application has also been submitted in a large number of additional territories such as Japan and China. In these territories, examination is ongoing.

"Thanks to the approvals in both Europe and the US, we have a very strong patent position in the most important territories," says Göran Forsberg, CEO of Cantargia. "We now have approvals regarding the treatment of various cancers with antibodies against IL1RAP in general as well as for the CAN04 antibody"

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the above contact person at 11.00 CET on 6 October 2017. 

About us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in leukemia stem cells, later research has also identified IL1RAP in a large number of other forms of cancer. The lead compound, CAN04 directed against IL1RAP, will be investigated in the CANFOUR phase I/IIa clinical trial in with primary focus on non-small lung cancer and pancreatic cancer. CAN04 has a dual mechanism of action, it blocks IL1RAP function and stimulates the immune system to eradicate tumor cells. Cantargia’s second project is in discovery phase with the goal to develop an IL1RAP binding antibody optimized for therapy of autoimmunity and inflammatory diseases.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.


wkr0006.pdf